This is a non-interventional, study to assess demographic characteristics and patient reported outcomes in China patients with SEA treated with benralizumab - SPEED

Inclusion Criteria

• -Patients are eligible to be included in the study only if all of the following criteria apply:
• • Patients must to be 12 years old (inclusive) at the time of signing the informed consent.
• • Patients with severe eosinophilic asthma prescribed with benralizumab at the discretion of the clinician.
• • Blood EOS≥150/ul in the 3 months prior to or EOS≥300/ul in the 1 year prior to the time of signing the informed consent.
• • Participating patients and/or their legally authorized representative must provide signed and dated written informed consent form prior to any study specific procedures.